SHAHROKH F. SHARIAT, MD
Professor and Chairman
Department of Urology, Comprehensive Cancer Center
Medical University of Vienna, Vienna General Hospital
Adjunct Professor of Urology and Medical Oncology
Weill Cornell Medical Center, New York, NY, USA
Adjunct Professor of Urology
University of Texas Southwestern Medical Center, Dallas, TX, USA
Faculty of Medicine, Charles University, Prague, CZ
Dr. Shariat is currently professor and chairman of the department of urology, Medical University of
Vienna, Vienna General Hospital, Vienna, Austria. He is also adjunct professor of urology and medical
oncology at Weill Cornell Medical Center, New York, NY, adjunct professor of urology at the University
of Texas Southwestern Medical Center, Dallas, TX, USA, and guest professor at the Faculty of Medicine,
Charles University, Prague, CZ.
He has published more than 1100 peer-reviewed research papers (Scopus h-index 86, 30883 citations;
Google scholar h-index 118, 75020 citations), >350 non-peer-reviewed papers, and 18 book chapters. He
is the holder of four patents stemming from his research into prostate and bladder cancer, and is the
recipient of various national and international rewards. He has, for example, received the prestigious
Matula Award from the European Urological Association and the Gold Cystoscope 2017 from the
American Urological Association.
He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research
Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma
Collaboration) and prospective clinical trials. He is a member of various academic societies and a
journal, meeting abstract, and grant reviewer for numerous national and international organizations. He is
an editorial board member of various journals including European Urology, BJU International, World
Journal of Urology, Current Opinion in Urology (editor in chief), and Immunotherapy among others. He
heads a medical charity for refugees and is on the medical advisory board for two other charities.
His research focuses on urologic oncology – molecular mechanisms, markers, early detection, natural
history, treatment, translational and outcomes research. Specially, Dr. Shariat has been working on the
discovery, testing and validation of molecular markers associated with the biological and clinical behavior
of prostate and urothelial cancers. His laboratory research focuses on integrative genomics and
epigenomics of urothelial carcinoma with the goal of designing personalized therapeutic strategies.